AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Regional Media News

Oct 20 (Reuters) - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% of patients with a type of chronic inflammatory disorder of the esophagus. The result builds on August data, when AstraZeneca said the [...]

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial

Oct 20 (Reuters) - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% of patients ​with a type of chronic inflammatory disorder of ‌the esophagus. The result builds on Aug...

Tezspire Trial Shows Higher EoE Remission Through 52 Weeks

At 24 weeks, histologic remission reached 64.8% and 68.9% across two doses, versus 3.5% with placebo; swallowing symptom scores also fell.